These Snca flox delta neo mice possess loxP sites on either side of the first coding exon (exon II) of the targeted gene. When these mutant mice are bred to mice that express Cre recombinase, resulting offspring will have the first coding exon deleted in the cre-expressing tissues. Removal of the floxed sequence creates a null allele.
Mice that are homozygous for this allele are viable and fertile. The Donating Investigator reports that Western blot analysis of total protein extracts from several regions of the brain indicate that expression of the targeted mutation allele is similar to that observed in wildtype mice. When crossed with transgenic mice expressing Cre recombinase under the control of the actin promoter, no expression of alpha-synuclein protein was detected in the resulting mice by Western blot analysis. 



Mutations in human SNCA that result in aberrant polymerization and fibrillar aggregations are associated with neurodegenerative synucleinopathies, such as Parkinson's disease and multiple system atrophy.

These floxed mutant mice possess loxP sites flanking the first coding exon of the Snca gene. This strain may be useful for generating conditional mutations in applications related to neurodegenerative synucleinopathies, such as Parkinson's disease and multiple system atrophy.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.